NYSE Arca · OGEN
Oragenics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OGEN: Nov 6, 2026
Oragenics Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.96.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Quiver Quantitative- RTTNews · Jul 8, 2:34 AM EDTOragenics Activates Third Site For Phase 2a Of ONP-002 In Treating Concussions, Data By Q4 '26(RTTNews) – Oragenics (OGEN), a clinical-stage biotechnology company, on Tuesday reported the activation of a third site in Australia for the Phase 2a trial for ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
- RTTNews · Apr 20, 10:41 PM EDTOragenics Advances Phase IIa Trial Of ONP-002 For Concussion(RTTNews) – Oragenics, Inc. (OGEN) has reported early progress in its Phase IIa clinical trial of ONP-002, a proprietary intranasal neurosteroid being developed for mild traumatic brain injury (mTBI), and confirmed that two patients have been enrolled and eight study drug doses a
- RTTNews · Apr 14, 4:51 AM EDTOragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002(RTTNews) – Oragenics Inc. (OGEN), a clinical-stage biotechnology company, on Monday announced the dosing of the first patient in the Phase 2a trial for ONP-002, the company's lead candidate for treating concussions and mild traumatic brain injury (mTBI).
- RTTNews · Mar 12, 10:30 AM EDTOragenics Kick Off Phase IIa Trial Operations For ONP-002; Stock Up(RTTNews) – Oragenics, Inc. (OGEN) has officially launched clinical operations for its Phase IIa trial of ONP-002, completing the first site-initiation visit in Australia- a key step that moves the program from regulatory preparation into active trial execution.
- RTTNews · Jul 16, 1:53 PM EDTOragenics Partners With Sterling For U.S.-Based Manufacturing Of Concussion Drug ONP-002(RTTNews) – Oragenics, Inc. (OGEN) has entered into a manufacturing agreement with Sterling Pharma Solutions for the GMP production of ONP-002, its intranasal drug candidate for treating concussions.
- Quiver Quantitative · Jul 2, 4:21 PM EDTOragenics, Inc. Successfully Closes $16.5 Million Public Offering of Series H Convertible Preferred Stock and WarrantsOragenics closed a public offering, raising $16.5 million for its concussion drug development and general corporate purposes.
- Quiver Quantitative · Jul 1, 8:44 AM EDTOragenics, Inc. Announces $20 Million Public Offering of Series H Convertible Preferred Stock and WarrantsOragenics plans to offer 800,000 shares of preferred stock and warrants, aiming to raise $20 million for clinical trials and operations.
- Quiver Quantitative · Jun 16, 6:16 PM EDTInsider Sale: 10% owner at $OGEN Sells 5,000 SharesHealth, Inc. Odyssey, a 10% owner of $OGEN, sold 5,000 shares of the company on 06-13-2025 for an estimated $21,349. We received data on the trade from a recent SEC filing. This was a sale of approximately 29.3% of their shares of this class of stock. Following this trade, they n
- Quiver Quantitative · Jun 10, 9:00 AM EDTOragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society SymposiumOragenics will present its intranasal therapy ONP-002 for concussions at two upcoming international neuroscience events.
- Quiver Quantitative · May 12, 8:44 AM EDTOragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion TreatmentOragenics will host a webinar on May 20, 2025, to discuss its concussion treatment candidate ONP-002.
- Quiver Quantitative · Apr 23, 8:42 AM EDTOragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and ManagementOragenics will present research on its mTBI trial at the Annual Traumatic Brain Injury Conference in Boston.
- Quiver Quantitative · Mar 18, 5:40 PM EDTOragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit OpinionOragenics filed its 2024 Annual Report, highlighting an unqualified audit opinion and its commitment to advancing innovative treatments.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Oragenics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.